Report Overview

The Global Breast Cancer drugs market size stood at USD 23.03 billion in 2020 and is expected to rise to USD 51.95 billion by the end of 2028 exhibiting a CAGR of approximately 10.7% during the forecast period.

Between 15 and 20 Swedish women receive the diagnosis of breast cancer, making this the most common cancer in women. Globocan 2020 claims that this accounted for 12.1% of all the cases among both the sexes in Sweden. Breast cancer occupies the fifth position in the list of all cancer deaths in Sweden.

This is formed in the lobules, duct, fatty tissue or fibrous connective tissue in the breasts. While this cancer does not have any symptoms in its early stages, a lump in the breast can be the first sign of development. Breast cancer being the foremost cause for death due to cancers in women, offers innumerable opportunities to the pharmaceutical companies to launch new products that treat the illness.



Market Drivers

The increased prevalence and rise in number of new cases drives the Sweden Breast cancer drugs market. Sweden, being a developed country contributes to the risk factors associated with breast cancer. The rise in number of cases increases the demand for the breast cancer drugs which boost market growth. Increased per capita spending on healthcare in Sweden is one of the key drivers of market growth. There has been an increased awareness towards breast cancer in the recent years which paves way for early diagnosis. This in turn leads the way for prolonged survival, further creating a demand for drugs, propelling the market growth.